Compounds > erlotinib hydrochloride
Page last updated: 2024-09-05

erlotinib hydrochloride and decursin

erlotinib hydrochloride has been researched along with decursin in 1 studies

Compound Research Comparison

Studies
(erlotinib hydrochloride)		Trials
(erlotinib hydrochloride)		Recent Studies (post-2010)
(erlotinib hydrochloride)		Studies
(decursin)		Trials
(decursin)		Recent Studies (post-2010) (decursin)
4,3537863,033139191

Protein Interaction Comparison

ProteinTaxonomyerlotinib hydrochloride (IC50)decursin (IC50)
Amine oxidase [flavin-containing] AHomo sapiens (human)1.76

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Bhat, TA; Dheeraj, A; Nambiar, DK; Singh, RP; Singh, SP; Yim, DS1

Other Studies

1 other study(ies) available for erlotinib hydrochloride and decursin

ArticleYear
Decursin inhibits EGFR-ERK1/2 signaling axis in advanced human prostate carcinoma cells.
    The Prostate, 2023, Volume: 83, Issue:6

    Topics: Carcinoma; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Ligands; Male; MAP Kinase Signaling System; Phosphorylation; Prostate; Prostatic Neoplasms

2023